ArticleCardiovascular drugs and therapy2017
Primary Care Physician Perspectives on Barriers to Statin Treatment.
Article in Cardiovascular drugs and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis.Implementation science : IS · 2021Pooled it
- Pooled it
- The Statin Paradox: Drivers and Consequences of Therapy Discontinuation.Metabolites · 2026Review
- Identifying priority challenges of older adults with COPD: A multiphase intervention refinement study.Journal of the American Geriatrics Society · 2024Article
- Lipid-Lowering Therapy after Acute Coronary Syndrome.Journal of clinical medicine · 2024Review
- Comparison of the effect of 40 and 80 mg/day doses of atorvastatin on changes in lipid profiles among acute coronary syndrome patients: A randomized clinical trial study.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Article
- Medical knowledge about COVID-19 is travelling at the speed of mistrust: why this is relevant to primary care.Family practice · 2022Article
- A Cohort Analysis of Statin Treatment Patterns Among Small-Sized Primary Care Practices.Journal of general internal medicine · 2022Article
- Article
- LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model.Scientific reports · 2021Article
- Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review.Journal of the American Heart Association · 2020Review
- Impact of lowering the risk threshold for statin treatment on statin prescribing: a descriptive study in English primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2020Article
- Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription.Journal of the American Heart Association · 2019Article
- Statin-Associated Muscle Disease: Advances in Diagnosis and Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).The American journal of cardiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeDiscontinuation of statin therapy represents a major challenge for effective cardiovascular disease prevention. It is unclear how often primary care physicians (PCPs) re-initiate statins and what barriers they encounter. We aimed to identify PCP perspectives on factors influencing statin re-initiation.
methodsWe conducted six nominal group discussions with 23 PCPs from the Deep South Continuing Medical Education network. PCPs answered questions about statin side effects, reasons their patients reported for discontinuing statins, how they respond when discontinuation is reported, and barriers they encounter in getting their patients to re-initiate statin therapy. Each group generated a list of responses in round-robin fashion. Then, each PCP independently ranked their top three responses to each question. For each PCP, the most important reason was given a weight of 3 votes, and the second and third most important reasons were given weights of 2 and 1, respectively. We categorized the individual responses into themes and determined the relative importance of each theme using a "percent of available votes" metric.
resultsPCPs reported that side effects, especially muscle/joint-related symptoms, were the most common reason patients reported for statin discontinuation (47% of available votes). PCPs reported statin re-challenge as their most common response when a patient discontinues statin use (31% of available votes). Patients' fear of side effects was ranked as the biggest challenge PCPs encounter in getting their patients to re-initiate statin therapy (70% of available votes).
conclusionPCPs face challenges getting their patients to re-initiate statins, particularly after a patient reports side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.